BMS 190394

Drug Profile

BMS 190394

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 18 Jan 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 18 Jan 2005 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
  • 05 Mar 1998 Preclinical development for Inflammation in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top